Polatuzumab vedotin
- Generic Name
- Polatuzumab vedotin
- Brand Names
- Polivy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1313206-42-6
- Unique Ingredient Identifier
- KG6VO684Z6
- Background
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrul...
- Indication
Polatuzumab vedotin is used in combination with bendamustine and rituximab to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. In Canada, this indication is approved for patients who are not eligible for autologous stem cell transplant and have received at least one p...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma, High-grade B Cell Lymphoma (HGBCL), Large B Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT06047080
- Locations
- 🇩🇪
Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany
🇺🇸Kaiser Permanente Medical Ctr, Vallejo, California, United States
🇺🇸St. Luke's Hospital, Chesterfield, Missouri, United States
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT06040320
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06015880
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT05954910
- Locations
- 🇨🇳
Third Xiangya Hospital of Central South University, Changsha, China
🇨🇳Xiangya Hospital of Centre-South University, Changsha, China
🇨🇳The Affiliated Hospital Of Qingdao University, Qingdao, China
Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 125
- Registration Number
- NCT05798156
- Locations
- 🇦🇹
Uniklinik Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinikum Magdeburg, Magdeburg, Sachsen-Anhalt, Germany
🇩🇪Uniklinikum Düsseldorf, Düsseldorf, Germany
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Biological: Axicabtagene CiloleucelProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideBiological: MosunetuzumabOther: Patient ObservationDrug: FludarabineDrug: Polatuzumab VedotinBiological: Lisocabtagene MaraleucelProcedure: Positron Emission TomographyBiological: Tisagenlecleucel
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 396
- Registration Number
- NCT05633615
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05615636
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Procedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: DoxorubicinDrug: PrednisoneBiological: RetifanlimabBiological: Rituximab and Hyaluronidase HumanBiological: TafasitamabDrug: VincristineProcedure: Bone Marrow AspirationProcedure: Multigated Acquisition ScanOther: Fludeoxyglucose F-18Procedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Biospecimen CollectionDrug: Polatuzumab Vedotin
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 35
- Registration Number
- NCT05455697
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 34
- Registration Number
- NCT05410418
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.